The Exodeoxyribonuclease III pipeline drugs market research report outlays comprehensive information on the Exodeoxyribonuclease III targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Exodeoxyribonuclease III pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, and Undisclosed which include the indications Solid Tumor, Unspecified Cancer, and Unspecified. It also reviews key players involved in Exodeoxyribonuclease III targeted therapeutics development with respective active and dormant or discontinued products.
The Exodeoxyribonuclease III pipeline targets constitutes close to six molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Preclinical, and Discovery stages are 5, and 1 respectively.
Exodeoxyribonuclease III overview
Exodeoxyribonuclease III (ExoIII) is a highly conserved enzyme involved in the repair and processing of DNA molecules in various organisms. As an exonuclease, ExoIII functions by cleaving nucleotides sequentially from the 3′ end of a DNA strand, playing a crucial role in maintaining genomic integrity. One of the primary functions of ExoIII is its involvement in the base excision repair (BER) pathway, a critical mechanism for addressing DNA damage caused by oxidative stress and various chemical agents. In BER, damaged or mismatched bases are recognized and removed, and ExoIII participates in the subsequent step by excising the remaining nucleotides in the vicinity of the lesion. ExoIII is particularly known for its ability to process DNA with damaged termini. It exhibits strong 3′-to-5′ exonuclease activity, making it effective in cleaving damaged or mismatched bases, as well as in removing overhangs or protruding ends in DNA molecules. This functionality is essential for the repair of DNA lesions and the maintenance of the overall stability of the genome. Beyond its role in DNA repair, ExoIII is utilized as a tool in molecular biology and genetic research. Researchers often employ ExoIII to create single-stranded DNA regions for various applications, including DNA sequencing, site-directed mutagenesis, and the generation of DNA probes.
For a complete picture of Exodeoxyribonuclease III’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
